期刊
GENETICS IN MEDICINE
卷 24, 期 11, 页码 2296-2307出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.gim.2022.07.022
关键词
Chromosomal microarray; Clinical diagnostics; FMR1 analysis; Genome sequencing; Intellectual disability
This study compared the results of different diagnostic approaches in individuals with intellectual disability/neurodevelopmental disorders and found that genome sequencing (GS) performed as a first-line test had a higher diagnostic yield of 35% compared to other strategies. GS has the potential to replace traditional methods such as chromosomal microarray (CMA) and FMR1 analysis, offering advantages in terms of diagnostic time and cost.
Purpose: Individuals with intellectual disability (ID) and/or neurodevelopment disorders (NDDs) are currently investigated with several different approaches in clinical genetic diagnostics. Methods: We compared the results from 3 diagnostic pipelines in patients with ID/NDD: genome sequencing (GS) first (N = 100), GS as a secondary test (N = 129), or chromosomal microarray (CMA) with or without FMR1 analysis (N = 421). Results: The diagnostic yield was 35% (GS -first), 26% (GS as a secondary test), and 11% (CMA/FMR1). Notably, the age of diagnosis was delayed by 1 year when GS was performed as a secondary test and the cost per diagnosed individual was 36% lower with GS first than with CMA/FMR1. Furthermore, 91% of those with a negative result after CMA/FMR1 analysis (338 individuals) have not yet been referred for additional genetic testing and remain undiagnosed. Conclusion: Our findings strongly suggest that genome analysis outperforms other testing strategies and should replace traditional CMA and FMR1 analysis as a first-line genetic test in individuals with ID/NDD. GS is a sensitive, time-and cost-effective method that results in a confirmed molecular diagnosis in 35% of all referred patients. (c) 2022 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据